Edwards Lifesciences (EW) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Edwards Lifesciences Revenue Highlights

Latest Revenue (Y)

$6.00B

Latest Revenue (Q)

$1.35B

Main Segment (Y)

Transcatheter Aortic Valve Replacement

Main Geography (Y)

UNITED STATES

Edwards Lifesciences Revenue by Period

Edwards Lifesciences Revenue by Year

Date	Revenue	Change
2023-12-31	$6.00B	11.56%
2022-12-31	$5.38B	2.86%
2021-12-31	$5.23B	19.29%
2020-12-31	$4.39B	0.88%
2019-12-31	$4.35B	16.79%
2018-12-31	$3.72B	8.37%
2017-12-31	$3.44B	15.91%
2016-12-31	$2.96B	18.85%
2015-12-31	$2.49B	7.35%
2014-12-31	$2.32B	13.56%
2013-12-31	$2.05B	7.68%
2012-12-31	$1.90B	13.17%
2011-12-31	$1.68B	16.01%
2010-12-31	$1.45B	9.51%
2009-12-31	$1.32B	6.76%
2008-12-31	$1.24B	13.44%
2007-12-31	$1.09B	5.22%
2006-12-31	$1.04B	3.92%
2005-12-31	$997.90M	7.13%
2004-12-31	$931.50M	8.25%
2003-12-31	$860.50M	22.23%
2002-12-31	$704.00M	1.73%
2001-12-31	$692.00M	-13.93%
2000-12-31	$804.00M	-11.16%
1999-12-31	$905.00M	-

Edwards Lifesciences generated $6.00B in revenue during NA 2023, up 11.56% compared to the previous quarter, and up 161.30% compared to the same period a year ago.

Edwards Lifesciences Revenue by Quarter

Date	Revenue	Change
2024-09-30	$1.35B	-2.27%
2024-06-30	$1.39B	-13.28%
2024-03-31	$1.60B	4.18%
2023-12-31	$1.53B	3.59%
2023-09-30	$1.48B	-3.22%
2023-06-30	$1.53B	4.84%
2023-03-31	$1.46B	8.25%
2022-12-31	$1.35B	2.22%
2022-09-30	$1.32B	-4.00%
2022-06-30	$1.37B	2.44%
2022-03-31	$1.34B	0.86%
2021-12-31	$1.33B	1.49%
2021-09-30	$1.31B	-4.78%
2021-06-30	$1.38B	13.10%
2021-03-31	$1.22B	2.09%
2020-12-31	$1.19B	4.45%
2020-09-30	$1.14B	23.34%
2020-06-30	$925.00M	-18.05%
2020-03-31	$1.13B	-3.87%
2019-12-31	$1.17B	7.32%
2019-09-30	$1.09B	0.65%
2019-06-30	$1.09B	9.46%
2019-03-31	$993.00M	1.56%
2018-12-31	$977.70M	7.84%
2018-09-30	$906.60M	-3.93%
2018-06-30	$943.70M	5.46%
2018-03-31	$894.80M	0.71%
2017-12-31	$888.50M	8.16%
2017-09-30	$821.50M	-2.41%
2017-06-30	$841.80M	-4.72%
2017-03-31	$883.50M	15.08%
2016-12-31	$767.70M	3.83%
2016-09-30	$739.40M	-2.62%
2016-06-30	$759.30M	8.89%
2016-03-31	$697.30M	3.90%
2015-12-31	$671.10M	9.03%
2015-09-30	$615.50M	-0.21%
2015-06-30	$616.80M	4.49%
2015-03-31	$590.30M	-4.48%
2014-12-31	$618.00M	1.75%
2014-09-30	$607.40M	5.62%
2014-06-30	$575.10M	10.09%
2014-03-31	$522.40M	-2.54%
2013-12-31	$536.00M	8.15%
2013-09-30	$495.60M	-4.18%
2013-06-30	$517.20M	4.13%
2013-03-31	$496.70M	-2.70%
2012-12-31	$510.50M	13.98%
2012-09-30	$447.90M	-7.07%
2012-06-30	$482.00M	4.97%
2012-03-31	$459.20M	6.74%
2011-12-31	$430.20M	4.24%
2011-09-30	$412.70M	-4.29%
2011-06-30	$431.20M	6.60%
2011-03-31	$404.50M	3.08%
2010-12-31	$392.40M	12.47%
2010-09-30	$348.90M	-4.46%
2010-06-30	$365.20M	7.25%
2010-03-31	$340.50M	-1.79%
2009-12-31	$346.70M	6.45%
2009-09-30	$325.70M	-2.92%
2009-06-30	$335.50M	7.02%
2009-03-31	$313.50M	1.23%
2008-12-31	$309.70M	2.01%
2008-09-30	$303.60M	-7.33%
2008-06-30	$327.60M	10.38%
2008-03-31	$296.80M	-

Edwards Lifesciences generated $1.35B in revenue during Q3 2024, up -2.27% compared to the previous quarter, and up 88.51% compared to the same period a year ago.

Edwards Lifesciences Revenue Breakdown

Edwards Lifesciences Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Transcatheter Mitral And Tricuspid Therapies	$197.60M	$116.10M	$86.00M	$41.80M	$28.20M
Critical Care	$928.10M	$855.00M	$834.90M	$725.40M	$740.20M
Surgical Heart Valve Therapy	$999.30M	$893.10M	$889.10M	$761.80M	$841.70M
Transcatheter Aortic Valve Replacement	$3.88B	$3.52B	$3.42B	$2.86B	-
Transcatheter Heart Valves	-	-	-	-	$2.74B

Edwards Lifesciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Transcatheter Aortic Valve Replacement (64.61%), Surgical Heart Valve Therapy (16.64%), Critical Care (15.46%), and Transcatheter Mitral And Tricuspid Therapies (3.29%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Transcatheter Heart Valves	$1.02B	$1.04B	$1.01B	$979.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transcatheter Mitral And Tricuspid Therapies	$91.10M	$83.00M	$72.90M	$56.00M	$52.40M	$47.60M	$41.60M	$31.50M	$29.70M	$27.90M	$27.00M	$25.30M	$22.30M	$22.10M	$16.30M	$13.10M	$12.10M	$6.10M	$10.50M	$7.20M
Surgical Heart Valve Therapy	$240.00M	$264.30M	$266.10M	$248.20M	$246.60M	$256.30M	$248.20M	$224.10M	$219.70M	$228.50M	$220.80M	$221.30M	$217.40M	$237.40M	$213.00M	$204.20M	$203.30M	$160.90M	$193.40M	$205.10M
Critical Care	-	-	$251.30M	$250.50M	$221.00M	$234.70M	$221.90M	$225.00M	$207.30M	$210.60M	$212.10M	$211.60M	$212.70M	$215.00M	$195.60M	$198.20M	$180.90M	$163.70M	$182.60M	$199.30M
Transcatheter Aortic Valve Replacement	-	-	-	$979.40M	$960.90M	$991.60M	$947.90M	$867.70M	$862.30M	$906.90M	$881.30M	$871.50M	$857.80M	$901.50M	$791.70M	$776.20M	$744.60M	$594.30M	$742.20M	-

Edwards Lifesciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Transcatheter Heart Valves (75.55%), Surgical Heart Valve Therapy (17.72%), and Transcatheter Mitral And Tricuspid Therapies (6.73%).

Edwards Lifesciences Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Europe	$1.33B	$1.17B	$1.19B	$973.60M	$941.20M
UNITED STATES	$3.51B	$3.13B	$2.96B	$2.52B	$2.53B
Rest of World	$709.20M	$601.40M	$550.20M	$435.80M	$429.40M
JAPAN	$452.40M	$473.60M	$528.90M	$460.10M	$444.70M

Edwards Lifesciences's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (58.43%), Europe (22.22%), Rest of World (11.81%), and JAPAN (7.53%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Rest of World	$148.60M	$146.10M	$178.90M	$182.80M	$180.30M	$180.80M	$165.30M	$150.90M	$158.00M	$147.40M	$145.10M	$141.90M	$140.00M	$138.70M	$129.60M	$125.30M	$111.20M	$97.30M	$102.00M	$114.40M
Europe	$319.80M	$335.60M	$367.80M	$344.90M	$322.30M	$336.20M	$331.10M	$290.80M	$270.10M	$302.80M	$311.10M	$309.40M	$291.10M	$309.80M	$280.00M	$265.80M	$253.80M	$204.70M	$249.30M	$242.20M
JAPAN	$81.40M	$87.40M	$110.80M	$112.00M	$108.40M	$117.90M	$114.10M	$111.10M	$104.10M	$122.90M	$135.50M	$138.90M	$125.90M	$131.80M	$132.30M	$129.40M	$113.90M	$106.80M	$110.00M	$120.30M
UNITED STATES	$804.60M	$816.80M	$940.70M	$894.40M	$869.90M	$895.30M	$849.10M	$795.50M	$786.80M	$800.80M	$749.50M	$739.50M	$753.20M	$795.70M	$674.70M	$671.20M	$662.00M	$516.20M	$667.40M	$697.20M

Edwards Lifesciences's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (59.41%), Europe (23.61%), Rest of World (10.97%), and JAPAN (6.01%).

Edwards Lifesciences Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ABT	Abbott Laboratories	$40.11B	$10.63B
MDT	Medtronic	$32.36B	$8.40B
SYK	Stryker	$20.50B	$5.49B
EW	Edwards Lifesciences	$6.00B	$1.35B
ALGN	Align	$3.86B	$977.87M
DXCM	DexCom	$3.62B	$994.20M
ZBH	Zimmer Biomet	$1.94B	$143.40M
PODD	Insulet	$1.70B	$372.60M
TNDM	Tandem Diabetes Care	$747.72M	$221.91M

EW Revenue FAQ

What is Edwards Lifesciences’s yearly revenue?

Edwards Lifesciences's yearly revenue for 2023 was $6B, representing an increase of 11.56% compared to 2022. The company's yearly revenue for 2022 was $5.38B, representing an increase of 2.86% compared to 2021. EW's yearly revenue for 2021 was $5.23B, representing an increase of 19.29% compared to 2020.

What is Edwards Lifesciences’s quarterly revenue?

Edwards Lifesciences's quarterly revenue for Q3 2024 was $1.35B, a -2.27% decrease from the previous quarter (Q2 2024), and a -8.54% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.39B, a -13.28% decrease from the previous quarter (Q1 2024), and a -9.43% decrease year-over-year (Q2 2023). EW's quarterly revenue for Q1 2024 was $1.6B, a 4.18% increase from the previous quarter (Q4 2023), and a 9.50% increase year-over-year (Q1 2023).

What is Edwards Lifesciences’s revenue growth rate?

Edwards Lifesciences's revenue growth rate for the last 3 years (2021-2023) was 14.76%, and for the last 5 years (2019-2023) was 38.10%.

What are Edwards Lifesciences’s revenue streams?

Edwards Lifesciences's revenue streams in c 23 are Transcatheter Mitral And Tricuspid Therapies, Critical Care, Surgical Heart Valve Therapy, and Transcatheter Aortic Valve Replacement. Transcatheter Mitral And Tricuspid Therapies generated $197.6M in revenue, accounting 3.29% of the company's total revenue, up 70.20% year-over-year. Critical Care generated $928.1M in revenue, accounting 15.46% of the company's total revenue, up 8.55% year-over-year. Surgical Heart Valve Therapy generated $999.3M in revenue, accounting 16.64% of the company's total revenue, up 11.89% year-over-year. Transcatheter Aortic Valve Replacement generated $3.88B in revenue, accounting 64.61% of the company's total revenue, up 10.28% year-over-year.

What is Edwards Lifesciences’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Edwards Lifesciences was Transcatheter Aortic Valve Replacement. This segment made a revenue of $3.88B, representing 64.61% of the company's total revenue.